TriSalus Life Sciences (NASDAQ:TLSI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of TriSalus Life Sciences (NASDAQ:TLSI) from a sell rating to a hold rating in a research report released on Friday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Tuesday, November 25th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, TriSalus Life Sciences has a consensus rating of “Moderate Buy” and an average price target of $10.50.

TriSalus Life Sciences Price Performance

NASDAQ TLSI opened at $6.82 on Friday. TriSalus Life Sciences has a fifty-two week low of $3.42 and a fifty-two week high of $6.91. The stock’s 50-day moving average is $4.86 and its two-hundred day moving average is $4.91. The firm has a market cap of $340.48 million, a P/E ratio of -3.37 and a beta of 0.42.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.79). The firm had revenue of $11.57 million during the quarter, compared to the consensus estimate of $11.76 million. TriSalus Life Sciences has set its FY 2025 guidance at EPS. On average, equities analysts expect that TriSalus Life Sciences will post -1.55 EPS for the current year.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of hedge funds have recently made changes to their positions in the business. Bank of America Corp DE lifted its stake in TriSalus Life Sciences by 1.8% during the second quarter. Bank of America Corp DE now owns 188,906 shares of the company’s stock worth $1,030,000 after purchasing an additional 3,374 shares during the period. Connective Capital Management LLC grew its stake in shares of TriSalus Life Sciences by 12.8% in the 2nd quarter. Connective Capital Management LLC now owns 32,796 shares of the company’s stock valued at $179,000 after purchasing an additional 3,717 shares during the period. Millennium Management LLC raised its holdings in shares of TriSalus Life Sciences by 17.7% in the 3rd quarter. Millennium Management LLC now owns 35,612 shares of the company’s stock worth $166,000 after buying an additional 5,359 shares in the last quarter. Police & Firemen s Retirement System of New Jersey bought a new position in shares of TriSalus Life Sciences during the 2nd quarter worth approximately $29,000. Finally, JPMorgan Chase & Co. lifted its position in shares of TriSalus Life Sciences by 35,804.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after buying an additional 7,519 shares during the period. Institutional investors and hedge funds own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.